Ammar Adam

Ammar Adam is a seasoned professional in pharmacology with extensive experience in the biotechnology field. Currently serving as Senior Director and Head of In vivo Pharmacology at Foghorn Therapeutics, Inc since August 2019, Ammar has played a key role in advancing clinical programs, notably FHD-609 and FH-286. Prior to this, Ammar held the position of Director of Pharmacology at Repare Therapeutics, where expertise was utilized to enhance animal capabilities. As Principal Scientist at Surface Oncology Inc., Ammar contributed to the clinical transition of several antibody molecule inhibitors. Ammar began a career at AstraZeneca as a Scientist, developing a strong foundation in pharmaceutical research and development.